	US 11,938,182 B2
	Halogenated xanthenes as vaccine adjuvants
Aru Narendran, Calgary (CA); Dominic Rodrigues, Knoxville, TN (US); Edward V. Pershing, Knoxville, TN (US); and Bruce Horowitz, Knoxville, TN (US)
Assigned to Provectus Pharmatech, Inc., Knoxville, TN (US); and UTI Limited Partnership, Calgary (CA)
Filed by Provectus Pharmatech, Inc., Knoxville, TN (US); and UTI Limited Partnership, Calgary (CA)
Filed on Sep. 29, 2021, as Appl. No. 17/488,430.
Application 17/488,430 is a continuation in part of application No. 17/212,723, filed on Mar. 25, 2021.
Claims priority of provisional application 63/000,231, filed on Mar. 26, 2020.
Prior Publication US 2022/0016242 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/39 (2013.01) [A61K 39/0011 (2013.01); A61K 2039/55511 (2013.01)]

9 Claims

1. A method of inducing Type I interferon (IFN) response in a mammalian subject that presents with a microbial infection that comprises administering a STING dimerization-inducing amount of a halogenated xanthene (HX), a pharmaceutically acceptable salt, an amide thereof whose nitrogen atom is unsubstituted, substituted with one or two C₁-C₄alkyl groups that are the same or different or together with the amido nitrogen form a 5- or 6-membered ring, a C₁-C₄alkyl ester thereof, an aromatic derivative thereof, wherein the aromatic derivative is an ester or amide formed from an alcohol or monosubstituted amine having a 5- or 6-membered aromatic ring, or a 5,6- or 6,6-fused aromatic ring system that contains 0, 1 or 2 hetero ring atoms that are independently nitrogen, oxygen or sulfur.